iMACnet is a collaborative research project that is funded by the Federal Ministry of Education and Research (BMBF). Based on the central hypothesis that genetically corrected induced pluripotent stem cell derived macrophages (i-MACs) constitute an easy, reliable, safe, and potentially highly standardized cell source for innovative cell therapies, the project aims to demonstrate a proof of concept in two severe congenital diseases affecting the myeloid cell compartment: hereditary Pulmonary Alveolar Proteinosis (herPAP) and Chronic Granulomatous Disease associated colitis (CGD-col).
iMACnet brings together clinicians as well as experts in cell and gene therapy from the Hannover Medical School ( Prof. Thomas Moritz, Prof. Gesine Hansen, Prof. Axel Schambach, Prof. Ulrike Köhl, Dr. Nico Lachmann and Dr. Robert Zweigerdt) and the Medical Center-University of Freiburg (Prof. Toni Cathomen and Prof. Philipp Henneke). The iMACnet project is a continuation of an established cooperation between the partner institutions, within the framework of which, the generation of iPSC-derived, genetically corrected, functional macrophages for both target diseases has been shown. In the context of the iMACnet project, the partners aim at establishing conditions for the clinical application of iMACs. To that end, the project focuses on developing GMP-compatible processes for the production of patient specific iPSC cell lines, their genetic repair by means of state of the art designer-nuclease technology as well as their expansion and differentiation into fully functional macrophages using bioreactor technology. Subsequently, the therapeutic efficacy and safety of the generated i-MACs will be evaluated in relevant murine models of CGD-col and herPAP.
October 16-19, 2018
26th Annual ESGCT Congress
April 29 - May 2, 2019
22nd Annual ASGCT Meeting